Patents by Inventor Kerry Harrison

Kerry Harrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders
    Publication number: 20090181939
    Abstract: Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors, such as obesity, wherein: R1 is aryl or heteroaryl; R2 is alkyl, aryl or heteroaryl; R3 is alkyl, aryl, heteroaryl, NR9R10, OR15, or NR16C(O)R17; Y is C?O, C?S, SO2, or (CR7R8)p; m=1 or 2; n=1 or 2; and p=1, 2, 3 or 4, R7 to R17 being as defined in the specification; wherein if —Y—R3 is C(O)NH(alkyl) then: R1 and/or R2 is selected from heteroaryl; and/or m and/or n is 2; and/or R11 and/or R12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Application
    Filed: March 19, 2009
    Publication date: July 16, 2009
    Applicant: VERNALIS RESEARCH LIMITED.
    Inventors: James Edward Paul Davidson, Jonathan Mark Bentley, Claire Elizabeth Dawson, Kerry Harrison, Howard Langham Mansell, Alan Leslie Pither, Robert Mark Pratt, Jonathan Richard Anthony Roffey, Victoria Jane Ruston
  • Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders
    Patent number: 7504522
    Abstract: Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors such as obesity: Formula (I) wherein: R1 and R2 are independently selected from aryl; and R3 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, wherein at least one of R1 and R2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [—CH—O—] group.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: March 17, 2009
    Assignee: Vernalis Research Limited
    Inventors: James Edward Paul Davidson, Claire Elizabeth Dawson, Kerry Harrison, Howard Langham Mansell, Robert Mark Pratt, Sukhjit Sohal, Victoria Jane Ruston
  • Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs
    Publication number: 20070173486
    Abstract: Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors, such as obesity, wherein: R1 is aryl or heteroaryl; R2 is alkyl, aryl or heteroaryl; R3 is alkyl, aryl, heteroaryl, NR9R10, OR15, or NR16C(O)R17; Y is C?O, C?S, SO2, or (CR7R8); m=1 or 2; n=1 or 2; and p=1, 2, 3 or 4, R7 to R17 being as defined in the specification; wherein if —Y—R3 is —C(O)NH(alkyl) then: R1 and/or R2 is selected from heteroaryl; and/or m and/or n is 2; and/or R11 and/or R12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Application
    Filed: April 29, 2004
    Publication date: July 26, 2007
    Applicant: VERNALIS RESEARCH LIMITED
    Inventors: James Davidson, Jonathan Bentley, Claire Dawson, Kerry Harrison, Howard Mansell, Alan Pither, Robert Pratt, Jonathan Roffey, Victoria Ruston
  • Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders
    Publication number: 20070054891
    Abstract: Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors such as obesity: Formula (I) wherein: R1 and R2 are independently selected from aryl; and R3 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, wherein at least one of R1 and R2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [—CH-0-] group.
    Type: Application
    Filed: April 29, 2004
    Publication date: March 8, 2007
    Inventors: James Davidson, Claire Dawson, Kerry Harrison, Howard Mansell, Robert Pratt, Suhkjit Sohal, Victoria Ruston